ORGO
vs
S&P 500
ORGO
S&P 500
Over the past 12 months, ORGO has significantly outperformed S&P 500, delivering a return of +49% compared to the S&P 500's +16% growth.
Stocks Performance
ORGO vs S&P 500
Performance Gap
ORGO vs S&P 500
Performance By Year
ORGO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Organogenesis Holdings Inc
Glance View
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.